Introduction
Dyslipidemia has emerged as a major long-term concern in individuals with HIV infection who are treated with combination antiretroviral therapy (ART) [1] [2] [3] . Data from the large, prospective data collection on adverse events of HIV drugs (D.A.D.) study suggests an increased cardiovascular risk, particularly in patients treated with protease inhibitors (PIs) , that is at least partially mediated by dyslipidemia [4, 5] . ART-associated dyslipidemia may include hypertriglyceridemia, decreased highdensity lipoprotein cholesterol (HDL-C) levels, and increased non-HDL-C (NHC) and low-density lipoprotein cholesterol levels [6] [7] [8] [9] [10] . Each of these lipid abnormalities is considered a cardiovascular risk factor by the National Cholesterol Education Program, Third Adult Treatment Program (NCEP-ATPIII) [11] , whose guidelines are also recommended for the treatment of dyslipidemia in HIV-infected patients [2] .
The type and severity of dyslipidemia may vary according to the ART regimen in use. Hypertriglyceridemia most frequently occurs during treatment with ritonavir (RTV) [6, 7] , whereas increased low-density lipoprotein cholesterol or NHC is a feature of several ART agents, including stavudine (d4T), PIs and non-nucleoside reverse transcriptase inhibitors (NNRTI), particularly efavirenz [6, 8, 9] . NNRTIs, particularly nevirapine, may be associated with increased HDL-C levels [6, 12] . Dyslipidemia does not, however, develop in all patients, despite similar ART exposure and comparable demographic, immunologic, and virologic characteristics. This discrepancy may be related to host genetic factors. We have reported an increased risk of dyslipidemia in HIV-infected carriers of unfavorable apolipoprotein E (APOE) and APOC3 genotypes, which was most pronounced in the setting of RTVcontaining ART [13] . A significant number of patients with abnormal lipid levels had favorable APOE and APOC3 genotypes, however, suggesting that additional genes modify the lipid response to ART. The aim of this study was to identify associations of plasma lipid levels during ART with additional genetic variants. To increase the validity of our results, the assessed gene variants were selected on the basis of the existing knowledge, that is, a previously published link to dyslipidemia. A second, exploratory aim was to evaluate appropriate methods to take into account the cumulative contribution of the different genetic variants to lipid levels, as a background for future studies of genetic testing before initiation of ART.
Patients and methods

Patients, antiretroviral therapy
Study participants were followed in the Swiss HIV Cohort Study (SHCS) (www.shcs.ch). The SHCS Genetics Project was approved by the ethics committees of all participating centers. Patients were included if they gave written, informed consent for genetic testing and were treated with ART during the study period which was from 1 January 1999 to 22 October 2005. The multiplicative, independent contribution of different antiretroviral drugs to plasma lipid levels was evaluated using regression modeling (see Statistical analysis). ART agents were distributed into groups according to published reports of their lipid effects [6] [7] [8] [9] [10] [12] [13] [14] [15] [16] and the results of the regression analysis (Table 1) . At each lipid determination, the specific ART medication and ART group in use was recorded. Lipid values were re-assigned to a new ART group or to 'no ART', respectively, if ART changes or interruptions were made. Thus, each participant could contribute lipid values to more than one ART group.
Lipids
All determinations of total cholesterol, HDL-C, and triglycerides (TG), made during the study period were included. NHC was calculated as NHC = total cholesterol -HDL-C. The fasting state was recorded for all blood draws. Sustained dyslipidemia was defined as > 2/3 of all lipid values of a participant during the study period being above/below the respective NCEP-ATPIII cutoff levels [TG: > 2.26 mmol/l (200 mg/dl); HDL-C: < 1.03 mmol/l (40 mg/dl); and NHC: > 4.9, 4.1, or 3.4 mmol/l (190, 160, and 130 mg/dl), respectively) [11] . Sustained dyslipidemia provides a clinically more relevant summary of an individual patient's plasma lipid status over time than single elevated or extreme values, as was selected in our previous report [13] .
Single nucleotide polymorphisms
Candidate SNPs were identified via review of PubMed reports of SNP associations with dyslipidemia in the general population, or among HIV-infected individuals. Following recommendations for the conduction of gene association studies [17] , the supporting reports are listed in detail herein (Supplementary Table 1 ). Genotyping methods, primers and probes are listed in Supplementary  Table 2 . Equivocal samples were retested and confirmed by a second observer. For quality assurance, 40 random samples per SNP were re-assayed, and two heterozygous and two homozygous samples for each of the common and rare allele were confirmed by direct sequencing. Results were entered into the central SHCS genetic database without knowledge of lipid values.
Genotype categories
The following, previously reported composite genotypes/ haplotypes were used: APOA5 [composite 64 G > C/ -1131 T > C haplogenotype: *1/*1 (common alleles) vs. non-*1/*1 haplotypes], and APOE (e3/e3 genotype vs. non-e3/e3 genotypes). Formal haplotype analysis was performed for the three APOC3 variants ( -482 C > T, -455 T > C, and 3238 C > G) and for the APOC3-APOA5 locus using Haploview [18] (accessible online at www.broad.mit.edu/mpg/haploview/). 
Statistical analysis
The data were analyzed longitudinally by modeling the individual effects of the different covariables on plasma lipid levels. We improved the model used in our previous report [13] , by using a multiplicative model with log 10 transformation of lipid values, to make the distribution more symmetric and stabilize variances. A multivariate model was used in which the covariance structure arises from consideration of three residual components [19, 20] , that is a variance components model. Advantages of this approach include the ability to accommodate unbalanced repeated measurements made at irregular time intervals [21] [22] [23] . To check for the weak stationarity assumption, the follow-up time scale was discretized annually and the Pearson's correlations of the ordinary least square residuals between the different time periods were calculated. In addition, inspection of a graph of the residuals over time, as well as of a scatter plot matrix were used [20, 21] . An informal check of the assumed covariance structure and the importance of each component can be gained by estimating nonparametrically the empirical semi-variogram [19, 24] .
Time-dependent covariables included in the regression model were ART regimen, age, body mass index, waist circumference, fasting state, treatment with lipid lowering agents, smoking status, CD4 + T cell count, and HIV viral load. Fixed covariables included were sex, presumed mode of HIV transmission, ethnicity, diabetes mellitus status, and the genetic factors assessed. The influence of ART and lipid lowering agents on lipid levels was assumed to be rapid and reversible [25] . For appropriate confounding adjustment, cross-sectional and longitudinal relationships between the continuous, timedependent explanatory variables and the response variable were distinguished [21, 26] , and adequate functional form was assessed using fractional polynomials [27] .
Model selection [28, 29] was based on confounding adjustment, Student t-test and Akaike information criterion. We started with a full model including all candidate SNPs and used a backward elimination procedure, removing at each step the least significant SNP, and re-estimating the model until a P-value < 0.05 for genetic variants and a plausible biological doseresponse relationship was obtained. To validate this selection procedure, starting from the selected model we sequentially re-introduced each SNP and compared the Akaike information criterion calculated on models with the same sample size. Adjustment for multiple testing was not performed, as the SNPs assessed had already been published and the goal of the study was to confirm previously reported associations [30, 31] . We assessed gene Â gene and gene Â drug interactions in the model [32, 33] . Goodness of fit was evaluated by comparing mean observed and predicted measurements as well as studentized conditional and marginal residuals on time plots. Different serial correlation processes, for example exponential or Gaussian correlation models, were investigated and compared by superimposition of the parametric and the nonparametric estimated variograms [19, 20, 24] .
We validated final regression models by using an established cross-validation procedure [34] . The Pearson correlation between the observed and predicted values was calculated to estimate the fit shrinkage [34] . Time plots of the prediction errors in both the log 10 and untransformed scales were also used to assess the predictive ability of the model. All statistical analyses were conducted using SAS version 9.1 (SAS Institute, Cary, North Carolina, USA) and STATA 9.2 (StataCorp, College Station, Texas, USA).
Results
Study participants
The characteristics of the participants are shown in Table 2 . Results are based on 404, 418, and 419 patients with no missing demographic or ART data and with successful genotyping of gene variants previously linked to TG, HDL-C, and NHC, respectively. The contribution of demographic variables to lipid levels was consistent with published reports (Table 3 ). The allelic frequencies and the distribution of genotypes were comparable with published frequencies in ethnically similar populations (Supplementary Table 1) . Each patient contributed a median of 10 lipid values (interquartile range, 9-12) during the study period (median follow-up, 4.8 years); overall, more than 4400 lipid values were analyzed. Participants with a median TG, HDL-C, and NHC level above the median for the study population contributed similar numbers of lipid values as did those with lower lipid levels (data not shown).
Contribution of antiretroviral therapy regimen to plasma lipid levels
A mean of 2.5 ART modifications were made during the study period (median, 2; IQR, 2-3). The contribution of ART to lipid levels was consistent with published reports (Tables 1 and 3 ). Compared with group 1, the populationaveraged, observed median TG levels during the study period were higher in participants treated with ART from the second (P = 0.01) and third (P < 0.001) groups. Median TG values were similar among participants receiving different regimens within each ART group, including those receiving different RTV doses, d4T, or both d4T and RTV (data not shown). For analysis of HDL-C, ART regimens were divided into three groups (Table 1) . Compared with group 1, observed median HDL-C levels were higher in the second (P = 0.001) and third (P < 0.001) groups. Median HDL-C values were similar for different regimens within each group, but higher during nevirapine (NVP) than efavirenz (EFV) exposure (1.31 vs. 1.25 mmol/l; P = 0.02). For NHC, ART regimens were divided into two groups (Table 1) . Compared with group 1, median NHC levels were higher in the second group (P < 0.001), but similar for different regimens within each group. The number of patients in each ART group is shown in Figs 1A (triglycerides), 2A (HDL-C), and 3 (NHC); note that the combined number of participants in the different ART groups is greater than the total number of study participants, because participants may contribute lipid values to several ART groups.
Contribution of single nucleotide polymorphisms to plasma lipid levels
No significant contribution to plasma TG, HDL-C, or NHC was identified in the present dataset for ADRB2 265 A > G and 298 C > G, LIPC -250 G > A, LIPG 584 C > T, LPL 1595 G > C, MDR1 3435 C > T, MTP -493 G > T, SCARB1 41 C > T, and TNF -308 G > A. All allelic frequencies and the contribution of SNPs to lipid levels are listed in Supplementary Table 1 .
Triglycerides
As shown in Table 3 , homozygous variant ABCA1 2962A > G, non-*1/*1 haplotypes of APOA5, and none3/e3 genotypes of APOE contributed to increased plasma TG levels, after adjusting for the nongenetic covariates. The increases in mean predicted TG levels were 0.57, 0.32, and 0.21 mmol, respectively. Homozygous variant CETP 279G > A was associated with a decrease in mean predicted TG levels of 0.24 mmol/l. Heterozygous carriers of each of these variants had no significant change in TG levels. The contribution of homozygous variant ABCA1 2962 A > G to increased TG levels was large, with evidence of a gene-dose effect, but has not been reported previously and thus should be considered exploratory. In two previous studies, significant TG elevations were seen in carriers of three APOC3 SNPs [13, 35] . Haplotype analysis confirmed the high degree of linkage disequilibrium among the three APOC3 SNPs [36, 37] . The simultaneous presence of all three SNPs on one chromosome (i.e. carriage of haplotype 8 in Supplementary  Table 3 ) was associated with an increase in TG levels (of 0.25 mmol/l), equivalent to that captured by the quantitative APOC3 variable used in previous reports [13, 35] . Haplotypes containing only 1 or 2 variants did not significantly contribute to TG levels. APOC3 and APOA5 polymorphisms are located in close proximity on chromosome 11q23. APOC3/APOA5 haplotypes reflected linkage dysequilibrium between APOA5 64G (associated with hypertriglyceridemia), and the common APOC3 -455T, indicating that the simultaneous presence of hypertriglyceridemic variants of both genes is uncommon on the same chromosome (data not shown). This supported separate analysis of the APOC3 and APOA5 loci. No relevant gene Â gene or gene Â ART group interactions were identified.
HDL-Cholesterol
Non-*1/*1-haplotypes of APOA5 contributed to decreased ( -0.12 mmol/l) mean predicted HDL-C levels (Table 3) . Heterozygous and homozygous variant CETP -629 C > A contributed to increased HDL-C levels, with evidence of a gene-dose effect (increase in mean predicted HDL-C levels; 0.11 and 0.25 mmol/l, respectively). A second CETP variant, 279 G > A, was in linkage disequilibrium with CETP -629 C > A, and only CETP -629 C > A was retained [38] . No gene Â gene or gene Â ART group interactions were identified.
Non-HDL-Cholesterol
Homozygous variants CETP -629 C > A and LIPG 584 C > T contributed to NHC levels ( Table 3) . As these effects have not been reported previously, they should be considered exploratory. No genotype Â genotype or genotype Â ART group interactions were identified.
Potential approaches to genetic prediction of antiretroviral therapy-related dyslipidemia
Taking into account concurrently multiple genetic variants and ART known to contribute to dyslipidemia has the potential to increase the accuracy of genetic prediction of dyslipidemia in ART-treated patients.
Triglycerides
Compared with a model that contained all covariables but no genetic information, a final model that considered the composite ABCA1/APOA5/APOC3/APOE/CETP genotype improved the Akaike information criterion by B20 points. To provide a clinically meaningful, illustrative summary of the results of the multivariate analysis, we added up, for each patient, the estimated regression coefficients of the genetic variants (i.e. the rounded numeric log 10 contribution to TG), multiplied by 100. Specifically, carriers of ABCA1 2962 GG, APOA5 non-*1/*1 haplotypes, APOC3 3-variant haplotype, and APOE non-e3/e3 genotypes, whose contribution to TG levels in regression analysis was 0.127 log 10 , 0.076 log 10 , 0.059 log 10 , and 0.051 log 10 mmol/l, respectively, received 13 points, eight points, six points, and five points, respectively. In carriers of CETP 279 GG, whose contribution to plasma TG levels in regression analysis was a -0.066 log 10 mmol/l reduction, seven points were subtracted. For illustrative purposes, we then divided the patients into three exploratory genotype scores: genotype score I (favorable), II (intermediate), and III (unfavorable) (Supplementary Table 4 ).
Observed, median TG levels during the study period were 1.47 and 2.27 mmol/l (P < 0.001) in participants with genotype scores I and III, respectively, when treated with regimens from ART group 1; and 2.63 and 4.12 mmol/l (P = 0.001), respectively, during RTV exposure (ART group 3). We then evaluated the contribution of ART group and genotype score to sustained, NCEP-ATPIIIdefined hypertriglyceridemia. Sustained hypertriglyceridemia was observed in 17 of 97 (17.5%) of participants with the most favorable gene-drug profile (Fig. 1) . This proportion was increased in those with a single unfavorable determinant (genetic or ART); 38 of 80 (47.5%; P < 0.001) individuals in ART group 3 with genotype score I, and 14 of 29 (48.3%; P = 0.001) individuals in ART group 1 and genotype score III. The highest risk of sustained hypertriglyceridemia was seen in those with both unfavorable genes and unfavorable ART; 15 of 24 individuals (66.7%); P < 0.001.
HDL-Cholesterol
Compared with a model that contained all covariables but no genetic information, a final model that considered the composite APOA5/CETP genotype improved the Akaike information criterion by B22 points. Analogous to analysis of TG, the estimated regression coefficients of the genetic variants, multiplied by 100, were added up. Specifically, carriers of CETP -629 CA and CETP -629 AA whose contribution to HDL-C levels in multivariate analysis was 0.031 log 10 and 0.069 log 10 mmol/l, received three points and seven points, respectively. In carriers of APOA5 non-*1/*1 haplotypes whose contribution to plasma HDL-C levels in regression analysis was a -0.038 log 10 mmol/l reduction in HDL-C levels, four points were subtracted. For illustrative purposes, we then divided the patients into three exploratory genotype scores: genotype score I (unfavorable), II (intermediate), and III (favorable) (Supplementary Table 5 ).
Observed, median HDL-C levels during the study period were 1.11 and 1.25 mmol/l (P < 0.001) in participants with genotype scores I and III, respectively, when treated with regimens from ART group 1; 1.15 and 1.31 mmol/l (P < 0.001) during PI exposure; and 1.17 and 1.50 mmol/l (P < 0.001) during NNRTI exposure. Sustained low HDL-C was observed in 11 of 15 (73.3%) of individuals with the most unfavorable APOA5/CETP-ART profile (Fig. 2) . This proportion was reduced in individuals with a single favorable determinant (genetic or ART); 6 of 15 (40%; P = 0.07) individuals in ART group 3 with genotype scores I, and 9 of 39 (23.1%; P = 0.001) individuals in ART group 1 and genotype score III. The lowest risk of sustained low HDL-C was seen in those with both favorable genes and favorable ART; 2 of 20 individuals (10%); P < 0.001.
Non-high-density lipoprotein-cholesterol
Compared with a model that contained all covariables but no genetic information, a final model that considered the composite CETP/LIPG genotype improved the Akaike information criterion by B3 points. The proportion of participants with sustained high NHC during PI-exposure or NNRTI-exposure was not influenced by the composite CETP/LIPG genotype (P = 0.71; data not shown).
Validation of multivariate models
Goodness of fit of the TG, HDL-C, and NHC models was excellent. The different residuals behaved appropriately and the parametric estimates of the variograms were close to the nonparametric estimates. Results were similar when the analysis was restricted to participants of Caucasian ethnicity, and when further adjusted for the presence of lipoatrophy (data not shown). Definitions of sustained dyslipidemia of different stringency (i.e. Z 1/ 2, Z 2/3, and Z 3/4 of an individual's lipid values above/below the NCEP-ATPIII threshold during the study period) gave similar results (data not shown).
Cross-validation showed shrinkage index values of 11% for TG, 10% for HDL-C, and 15% for NHC, suggesting that the models did not overfit and may be useful for prediction in other datasets.
Discussion
Major findings
In this study, we show that the genetic background influences the risk of dyslipidemia in HIV-infected patients during ART. The genetic risk of ART-associated dyslipidemia was defined through re-evaluation of 20 SNPs of 13 genes proposed in the literature as influencing plasma lipid levels. Using regression modeling, we were able to validate SNPs of five genes (ABCA1, APOA5, APOC3, APOE, and CETP) as contributing to hypertriglyceridemia, and SNPs of two genes (APOA5 and CETP) as contributing to low HDL-C. These data allowed the generation of genotype scores to provide a clinically meaningful, illustrative view of multigene-ART influences on lipid levels. Although variants of LIPG and CETP contributed to NHC levels, this association has not been previously reported and needs to be confirmed in other patient populations before it can be considered a true finding.
Experimental approach
Several SNPs proposed in the literature (ADRB2, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) did not contribute to plasma lipids in the present dataset, which may reflect a limited net effect of these SNPs, or the known difficulty to replicate and validate previously reported genetic associations [39, 40] . In view of such concerns, particular attention was paid to preliminary guidelines [17, 40] for the conduction of genetic association studies. We did not test any novel genes or SNPs but validated existing knowledge by selecting candidate genes/SNPs on the basis of their previously reported influence on lipid levels, mostly in HIVseronegative populations, and on biological plausibility. In general, SNPs with considerable evidence in the literature supporting a true lipid association were also retained in our final models. In contrast, SNPs with contradictory reports or limited documentation in the literature, mostly from single-time point, cross-sectional studies, were not associated with plasma lipid levels in the present study. As our study design was robust, by exploiting prospectively collected data analyzed longitudinally over > 4.5 years, representing more than 4400 lipid determinations, the most likely explication for our failure to validate certain SNPs are false-positive genetic associations in the literature. Cross-sectional studies are unable to account for the variability of lipid levels and other factors over time, whereas in our study, participants served as their own controls through periods of ART interruptions and modifications. The authors of an AIDS Clinical Trial Group study who evaluated the association of APOC3 variants with the lipid response to PI-based ART expressed concern that the single-time point, cross-sectional design of their study may have been statistically underpowered [41] . A randomized, clinical trial in ART-naive patients is the most rigorous study design to assess the lipid response to a small number of ART regimens, stratified by genetic background. A clinical trial is, however, unable to take into account interruptions and changes of ART or other factors over time, as can a cohort study, which more closely reflects the 'real life' situation of HIV clinical practice.
Exploratory genotype scores
Consistent with the current understanding of drugrelated dyslipidemia as the phenotypic expression of a complex genetic trait [42, 43] , there is evidence that consideration of multiple genetic variants increases the validity of predictive genetic testing [44] [45] [46] . In exploratory analyses, we present a genotype score that, in addition to considering the number of favorable or unfavorable genetic variants carried by the patient, also reflects the cumulative, net contribution of these variants to plasma lipids. Using this scoring system, the proportion of patients with sustained, NCEP-ATPIII-defined dyslipidemia varies considerably as a function of ART and the genetic background. We are fully aware that the scores were derived from and applied to the same dataset, and are thus exploratory. Nonetheless, the scores illustrate in which way predictive genetic testing might in the future be used in clinical practice. Effect of genotype score and ART group on predicted (adjusted) median plasma non-HDL-cholesterol levels. Box-and-whisker plot as in Fig. 1A . ART, antiretroviral therapy; HDL, high-density lipoprotein.
Study limitations
The multigene prediction model needs to be reproduced in an independent cohort or clinical trial. Future studies need to include a greater proportion of women and patients of non-Caucasian ethnicity, as the majority of participants were white men. In addition, the power of gene Â gene and gene Â drug interaction testing in our dataset was limited by the large number of possible interactions and the resulting small number of participants in some resulting strata. The prediction models and, ultimately, multiplexing genotyping systems, can be refined as we learn more about new SNPs that contribute to ART-related dyslipidemia. As an illustration of the limitation of our current prediction models, 18% of participants in this study had sustained hypertriglyceridemia and 10% had sustained low HDL-C, despite both favorable genes and favorable ART. Similarly, 33% of participants did not have sustained hypertriglyceridemia and 27% did not have low HDL-C, despite an unfavorable gene-drug profile.
Outlook
Technical improvements are now progressively lowering the cost of genotyping, which can be performed on a single occasion to identify patients at risk of dyslipidemia. If the accuracy of genetic prediction can be further improved, by consideration of additional gene variants and by the development of clinically useful multigene scoring systems, these findings may provide the background for prospective trials of the value of genotyping before ART initiation. The goal of multigene prediction is to avoid dyslipidemic ART regimens and their associated consequences, including the prescription of lipid lowering medication, polypharmacy, drug interactions, and, ultimately, increased cardiovascular risk.
